Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $208.8 million.

  • Gossamer Bio's Liabilities and Shareholders Equity fell 40.49% to $208.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 19.29%. This contributed to the annual value of $315.3 million for FY2024, which is 1.08% up from last year.
  • According to the latest figures from Q3 2025, Gossamer Bio's Liabilities and Shareholders Equity is $208.8 million, which was down 13.33% from $240.9 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's Liabilities and Shareholders Equity peaked at $373.4 million during Q2 2024, and registered a low of $181.7 million during Q2 2023.
  • For the 3-year period, Gossamer Bio's Liabilities and Shareholders Equity averaged around $281.0 million, with its median value being $280.6 million (2025).
  • Per our database at Business Quant, Gossamer Bio's Liabilities and Shareholders Equity surged by 105.48% in 2024 and then slumped by 40.49% in 2025.
  • Gossamer Bio's Liabilities and Shareholders Equity (Quarterly) stood at $272.4 million in 2022, then grew by 14.49% to $311.9 million in 2023, then rose by 1.08% to $315.3 million in 2024, then slumped by 40.49% to $208.8 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $208.8 million for Q3 2025, versus $240.9 million for Q2 2025 and $280.6 million for Q1 2025.